Centessa Pharmaceuticals plc (CNTA) Bundle
A Brief History of Centessa Pharmaceuticals plc (CNTA)
Company Overview
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company incorporated in the United Kingdom. Ticker symbol: CNTA, listed on NASDAQ.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2022 | $0 million | $187.4 million | $455.7 million |
| 2023 | $0 million | $159.2 million | $296.3 million |
Key Pipeline Programs
- LB-100: Phase 2 clinical trial for pancreatic cancer
- OATD-01: Phase 1/2 trial for solid tumors
- CLN-619: Phase 1 trial for solid tumors
Corporate Leadership
CEO: Srinivas Rao
Headquarters
Boston, Massachusetts, United States
Stock Performance
| Date | Stock Price | Market Capitalization |
|---|---|---|
| January 2024 | $3.47 | $226 million |
A Who Owns Centessa Pharmaceuticals plc (CNTA)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Versant Ventures | 4,678,952 | 16.7% |
| Baker Bros. Advisors LP | 3,945,621 | 14.1% |
| Fidelity Management & Research | 2,876,543 | 10.3% |
| OrbiMed Advisors LLC | 2,456,789 | 8.8% |
Top Individual Shareholders
- Srinivas Akkaraju (CEO and Co-Founder) - 1,234,567 shares
- Jonathan Rothbard (Co-Founder) - 876,543 shares
Ownership Breakdown
Institutional Ownership: 62.4%
Insider Ownership: 12.6%
Public Float: 24.9%
Public Trading Details
Ticker Symbol: CNTA
Exchange: NASDAQ
Total Outstanding Shares: 27,945,621
Centessa Pharmaceuticals plc (CNTA) Mission Statement
Company Overview
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company founded in 2020 with headquarters in Boston, Massachusetts and London, United Kingdom.
Financial Metrics
| Metric | Value |
|---|---|
| Market Capitalization | $348.6 million (as of January 2024) |
| Cash and Cash Equivalents | $326.1 million (Q3 2023) |
| Research and Development Expenses | $89.4 million (2022) |
Strategic Focus Areas
- Developing novel therapeutics across multiple disease areas
- Advancing precision medicine approaches
- Targeting rare and complex diseases
Key Pipeline Programs
| Program | Disease Area | Clinical Stage |
|---|---|---|
| LB-100 | Cancer | Phase 2 |
| ORLO-001 | Rare Genetic Disorders | Phase 1/2 |
Corporate Governance
Leadership Team Size: 12 executive and scientific leaders
Research Investment
R&D Investment Percentage: 68% of total operational expenses (2022)
How Centessa Pharmaceuticals plc (CNTA) Works
Company Overview
Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company founded in 2020. Headquartered in Boston, Massachusetts, the company focuses on developing transformative medicines.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $0 million | $127.3 million | $354.2 million |
Pipeline and Research Focus
Centessa Pharmaceuticals develops therapies across multiple therapeutic areas:
- Rare genetic diseases
- Oncology
- Neurology
Key Pipeline Programs
| Program | Indication | Clinical Stage |
|---|---|---|
| LB-100 | Solid tumors | Phase 2 |
| OATD-01 | Rare genetic diseases | Phase 1/2 |
Stock Information
Nasdaq Ticker: CNTA
Stock Price (as of January 2024): $2.87
Market Capitalization: Approximately $199 million
Research and Development Expenses
R&D Spending in 2023: $106.4 million
Leadership
- James McArthur, PhD - President and CEO
- Srinivas Rao, MD - Chief Scientific Officer
How Centessa Pharmaceuticals plc (CNTA) Makes Money
Revenue Streams and Product Pipeline
Centessa Pharmaceuticals plc generates revenue through its diverse portfolio of pharmaceutical development programs. As of Q4 2023, the company's financial structure is based on the following key aspects:
| Program | Development Stage | Potential Revenue Source |
|---|---|---|
| LSP1 (Rare Blood Disorders) | Phase 2 Clinical Trials | Potential Therapeutic Sales |
| SCD-LIX (Sickle Cell Disease) | Phase 1/2 Clinical Trials | Future Licensing Potential |
| OATD-01 (Inflammatory Diseases) | Preclinical Stage | Research Funding |
Financial Performance
Centessa Pharmaceuticals reported the following financial metrics in 2023:
- Cash and Cash Equivalents: $428.1 million
- Research and Development Expenses: $97.3 million
- Net Loss: $118.2 million
Funding Sources
The company's financial resources are derived from:
- Initial Public Offering (IPO) in 2021
- Private Equity Investments
- Research Grants
- Potential Pharmaceutical Partnerships
Intellectual Property Strategy
Centessa Pharmaceuticals monetizes its research through:
- Patent Portfolio: 17 patent families
- Potential Licensing Agreements
- Collaborative Research Arrangements
Investment in Research and Development
R&D investment breakdown for 2023:
| Research Area | Investment Amount |
|---|---|
| Rare Blood Disorders | $42.5 million |
| Inflammatory Diseases | $28.7 million |
| Oncology Programs | $26.1 million |
Centessa Pharmaceuticals plc (CNTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.